Key result
TEVAR with thoracic branch endoprosthesis yields ~3% aortic-related mortality at 5 years.
Why the study?
What are the 5-year clinical and durability outcomes of TEVAR with the Thoracic Branch Endoprosthesis in patients with aortic arch and proximal descending thoracic aortic aneurysms?
Cohort (n=40)
Nonrandomized
Yes
What are the 5-year clinical and durability outcomes of TEVAR with the Thoracic Branch Endoprosthesis in patients with aortic arch and proximal descending thoracic aortic aneurysms?
Five-year feasibility results of the Thoracic Branch Endoprosthesis for aortic arch aneurysms show high side-branch patency (94.8%), low aortic-related mortality (2.5%), and no treated-segment ruptures, though stroke risk (19.0%) warrants evaluation in larger cohorts.
Answers are grounded in this paper and cite their sources.
Supports feasibility for select arch aneurysms; leaves open randomized confirmation of stroke risk and durability.
To report final 5-year outcomes from prospective multicenter feasibility studies of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE) for aneurysms involving the proximal descending thoracic aorta and aortic arch (zones 0-2). Forty consecutive patients (23 male; mean age, 74±10 years) were enrolled at six sites in prospective, nonrandomized feasibility trials (2014-2016). Patients underwent TEVAR with proximal TBE in zone 0/1 (n=9; NCT02264977) or zone 2 (n=31; NCT02021812). A clinical events committee adjudicated aneurysm-related and all-cause mortality, major adverse events, and cerebrovascular events. Core laboratory analysis assessed endoleaks (types I-IV), aneurysm sac enlargement, device migration, and side branch patency. Five-year cumulative risk rates (2006 days) were estimated using Kaplan-Meier analysis. The median follow-up time among survivors was 60.2 months (range, 25.8 to 66.0), with 17 patients completing the required 5-year clinical and imaging follow-up across both studies. Eleven late deaths occurred; KM-estimated cumulative risk of 5-year all-cause mortality was 29% (95% CI: 17%-46%). One zone 2 death was adjudicated as aortic-related (2.5%; 95% CI: 0.4%-16%) due to ascending aortic rupture, with no ruptures occurring within treated aortic segments. Reintervention risk through 5 years was low (KM-estimated cumulative risk, 5.1%; 95% CI: 1.3%-19%), with two events, both in the zone 2 cohort. Five patients experienced stroke events through 5 years, corresponding to a KM cumulative risk of 19.0% ( 95% CI: 7.2%-43%), two in zone 2 and three in zone 0/1. Two patients had target vessel instability (5.0%, 95% CI: 0.6%-16.9%). Two side-branch patency events occurred in zone 2: one complete side-branch occlusion in the LSA associated with transient mild arm claudication and one asymptomatic partial occlusion, primary patency through 5-year follow-up was 94.8% (37/39 evaluable patients). Core laboratory identified endoleaks in 12 patients (30.8%; 95% CI: 15%-45%). Three patients (7.7%) had a type I or III endoleak by 5 years, all in the zone 2 arm; these included type IA in one patient (2.6%) and type III in two patients (5.1%). Additionally indeterminate (n=8, 20.5%) and type II (n=6, 15.4%) endoleaks were observed. Cumulative risk rate of aneurysm sac enlargement through 5-years was 15.0% for all patients (95% CI: 5.6%-30.3%), with events occurring in three zone 2 patients and one zone 0/1 patient. At 5 years, the early feasibility studies demonstrated excellent side branch patency, a low incidence of type IA endoleak, low aortic-related mortality, and no rupture within the treated aortic segments. Larger studies are needed to better define zone-specific cerebrovascular risk and long-term durability.
No takes yet. Share an insight, caveat, or question.
Maximus et al. (2026) conducted a cohort in Aneurysms involving the proximal descending thoracic aorta and aortic arch (zones 0-2) (n=40). Thoracic endovascular aortic repair (TEVAR) with GORE TAG Thoracic Branch Endoprosthesis (TBE) was evaluated on 5-year aortic-related mortality (95% CI 0.4%-16%). TEVAR with the Thoracic Branch Endoprosthesis yielded 2.5% aortic-related mortality and 94.8% primary side-branch patency at 5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: